Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 21;10(2):57.
doi: 10.3390/cancers10020057.

Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision

Kelsey E Lewis  1   2 , Karen H Lu  3   4 , Amber M Klimczak  5 , Samuel C Mok  6   7
Affiliations
Review

Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision

Kelsey E Lewis et al. Cancers (Basel). .

Abstract

Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The decisions involved in how a woman manages her BRCA mutation status can cause a great deal of stress and worry due to the imperfect therapy options. The goal of this review was to critically analyze the screening recommendations and alternative options for high-risk ovarian cancer patients and evaluate how these discrepancies and choices affect a woman's management decisions.

Keywords: BRCA; CA-125; ovarian cancer; risk-reducing surgery; screening guidelines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Cancer Statistics Center. [(accessed on 10 September 2017)]; Available online: https://cancerstatisticscenter.cancer.org/#!/
    1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010;60:277–300. doi: 10.3322/caac.20073. - DOI - PubMed
    1. Kuchenbaecker K.B., Hopper J.L., Barnes D.R., Phillips K., Mooij T.M., Roos-Blom M., Jervis S., van Leeuwen F.E., Milne R.L., Andrieu N., et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–2416. doi: 10.1001/jama.2017.7112. - DOI - PubMed
    1. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., Loman N., Olsson H., Johannsson O., Borg A., et al. Erratum: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 2003;73:709. doi: 10.1086/375033. - DOI - PMC - PubMed
    1. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007;25:1329–1333. doi: 10.1200/JCO.2006.09.1066. - DOI - PMC - PubMed